International Journal of Pharmaceutics 2015-08-01

Phthalimido-ferrocidiphenol cyclodextrin complexes: Characterization and anticancer activity.

Feten Najlaoui, Pascal Pigeon, Zaineb Abdelkafi, Sebastien Leclerc, Pierrick Durand, Mohamed El Ayeb, Naziha Marrakchi, Ali Rhouma, Gérard Jaouen, Stéphane Gibaud

Index: Int. J. Pharm. 491 , 323-34, (2015)

Full Text: HTML

Abstract

Several ferrocenyl analogues of tamoxifen have already showed strong antiproliferative activity in experimental glioma models. Nevertheless, these compounds are very poorly soluble in water and an adapted formulation is needed. In this work, we have tailored and optimized methylated cyclodextrin soluble complexes of phthalimido-ferrocidiphenol for the first time. The complexes were characterized, and the optimized formulation was tested for in vitro efficacy and cell proliferation assays on U87, human glioblastoma cancer cells. Molecular modeling can provide accurate information about the inclusion process. The inclusion of all the moieties at the same time (i.e., ferrocene, phthalimidylpropyl, 2 phenols) is not possible due to the steric hindrance of the 1:4 system. The 1:3 systems are possible but do not seem very relevant. However, various 1:2 and 1:1 complexes are mostly present in aqueous solutions. Some experiments have confirmed our hypothesis. First, interactions between the phenol, phthalimidylpropyl and ferrocenyl groups have been observed in our NMR experiments. Second, the inclusion of phthalimidylpropyl was detected by UV-vis spectrophotometry with an apparent 1:1 interaction, which was observed through the Benesi-Hildebrand method. The complex is readily soluble in water and keeps its pharmacological activity against U87 tumor cells (IC50=0.028 ± 0.007 μM vs. 0.018 ± 0.003 μM for PhtFerr).Copyright © 2015 Elsevier B.V. All rights reserved.